RXST - Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board | Benzinga
- Shareholders approved all agenda items and proposals of the Board of Directors
- Robert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of Directors
- Baruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory Board
- Oculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock
ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting held on May 29, 2024 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:30 p.m. CEST, including election of new members to its Board of Directors, as well as the recent appointment of two new members to its Scientific Advisory Board (SAB), and the establishment of a loan facility of up to CHF 50 million.
Annual General Meeting
The Company's shareholders approved all agenda items, including the election of new members to its Board of Directors.
The shareholders approved the 2023 Annual Report including the 2023 Annual (Statutory) Financial Statements and the 2023 Consolidated Financial Statements.
The shareholders acknowledged that the Company made a loss of CHF 41,396,417.34 with respect to the financial year ended December 31, 2023, and resolved that the balance sheet loss shall be carried forward to the new accounts.
The Members of the Board of Directors and the Executive Committee were granted discharge for their activities in 2023.
Anthony Rosenberg was re-elected as member and chairperson of the Board of Directors. Christina Ackermann, Lionel Carnot, Martijn Kleijwegt, Geraldine O'Keeffe and Riad Sherif were re-elected as members of the Board of Directors. Robert K. Warner and Arshad M. Khanani were elected as members of the Board of Directors. Christina Ackermann and Lionel Carnot were re-elected and Robert K. Warner was elected as members of the Compensation Committee. PricewaterhouseCoopers SA (Pully) was re-elected as Statutory Auditors. PST Legal AG (Zug) was elected as Independent Proxy.
The shareholders approved the compensation for the non-executive members of the Board of Directors:
- Total maximum amount of fixed (non-performance-related) compensation for the non-executive members of the Board of Directors until the end of the Company's 2025 Annual General Meeting: USD 522,855.
- Maximum value of equity or equity-based compensation for eight non-executive members of the Board of Directors until the end of the Company's 2025 Annual General Meeting: USD 1,215,000 (excluding employer social security and pension contributions).
The shareholders approved the compensation for members of the Executive Committee:
- Total maximum amount of fixed (non-performance-related) compensation for four members of the Executive Committee for the calendar year 2025 payable in 2025: USD 2,478,240.
- Total maximum amount of variable compensation for four members of the Executive Committee for the calendar year 2024 and payable in 2025 of USD 1,753,760.
- Maximum value of equity-based compensation for four members of the Executive Committee until the end of the calendar year 2025: USD 12,768,000 (excluding employer social security and pension contributions).
The shareholders provided a non-binding advisory vote on the 2023 Compensation Report of the Company.
The shareholders approved a capital band of 22'721'850 registered shares resulting in a capital band (taking into account the share issuance implemented on May 13, 2024) of CHF 464'437.00 to CHF 691'655.50 and the related amendment of the paragraphs 1 through 3 and paragraph 5 of article 3a of the articles of association in the form published on the website of the Company at https://investors.oculis.com/corporate-governance.
The shareholders approved a conditional share capital for bonds and similar debt instruments in the maximum amount of CHF 67'500.00 by the issuance of 6'750'000 registered shares and the related amendment of the paragraphs 1 and 2 of article 3b of the articles of association in the form published on the website of the Company at https://investors.oculis.com/corporate-governance.
The shareholders approved a conditional share capital for employees and individuals of comparable positions in the maximum amount of CHF 95'663.02 by the issuance of 9'566'302 registered shares and the related amendment of article 3c, paragraph 1 of the articles of association in the form published on the website ...